We have the cause of Alzheimer's all wrong, says neuroscientist
6 years, 9 months ago

We have the cause of Alzheimer's all wrong, says neuroscientist

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. The continued failure of new drugs to make a difference has to be interpreted as evidence that the amyloid protein is not the cause of Alzheimer’s disease. open image in gallery If brains cells don't get enough growth factor, they die When looking at brain tissue taken from deceased Alzheimer’s patients, researchers found that insulin lost its effectiveness as a growth factor, even in people who were not diabetic. Testing these drugs in animal models of another neurodegenerative disorder, Parkinson’s disease, also showed impressive effects, and two clinical trials in Parkinson’s patients showed good protective effects. To see any protective effect in the brain in a clinical trial is completely new, and it supports the new theory that Alzheimer’s and Parkinson’s disease are caused, at least in part, by a lack of growth factor activity in the brain.

Growth Disease Drugs Brain Cause Drug Living Well Factor Amyloid Brain Cells  factor  trials  amyloid  drug  diabetes  brain  wrong  neuroscientist  alzheimers  disease  drugs  growth  cause

History of this topic

Anti-amyloid therapy may keep Alzheimer’s symptoms at bay in certain patients, small study suggests
2 weeks, 1 day ago

Anti-amyloid therapy may keep Alzheimer’s symptoms at bay in certain patients, small study suggests

CNN  

CNN — For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the disease. “We like to call ourselves the X-Men because we are mutants, trying to save the world from Alzheimer’s disease,” said Marty Reiswig of Denver, …

The Race to Find a Cure for Alzheimer's
1 month, 3 weeks ago

The Race to Find a Cure for Alzheimer's

Bloomberg  

00:00 Alzheimer's disease affects millions and millions of Americans, but not just millions and millions of individual patients, but also orders of magnitude larger than that because of the effects on their families and their effects on larger society. But Schrag calls it a dead end, a view echoed in Pillar's new book, Doctored Fraud, Arrogance and Tragedy in the …

Why Alzheimer’s scientists are rethinking the amyloid hypothesis
2 months, 3 weeks ago

Why Alzheimer’s scientists are rethinking the amyloid hypothesis

Salon  

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive neurodegenerative disease that is characterized by cognitive decline. In June 2021, the Food and Drug Administration approved aducanumab, an amyloid beta-targeted drug, under the “accelerated approval” program for patients diagnosed with Alzheimer’s. To Eric Widera, a professor of medicine at the University of …

Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
2 months, 3 weeks ago

Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains

Live Mint  

-- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025. Companies including Biogen Inc. and Eli Lilly & Co. have spent billions of dollars on developing potential treatments, while others including Novo Nordisk A/S and Roche AG are also investigating the brain-destroying disease. “If we get a strong disease-modifying …

New Alzheimer's drug: only a few eligible for treatment
4 months, 2 weeks ago

New Alzheimer's drug: only a few eligible for treatment

NL Times  

It is estimated that less than one in ten people with dementia are eligible for treatment with Lecanemab or Leqembi, the slowing agent that is still allowed on the European market by the European Medicines Agency. That is why Alzheimer Nederland calls for a fast track "so that patients and their families are not unnecessarily in uncertainty for a long …

Alzheimer’s wonder drug blocked on NHS over cost
5 months, 1 week ago

Alzheimer’s wonder drug blocked on NHS over cost

The Telegraph  

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for the disease safe for use but the rationing body has immediately ruled that it is too expensive for NHS patients. The decision on donanemab – the second drug found to slow the progress of Alzheimer’s disease – mirrors that …

Researchers investigating if drugs can be repurposed to combat dementia
5 months, 2 weeks ago

Researchers investigating if drugs can be repurposed to combat dementia

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Prof Hooper said: “What we’re interested in – because …

Alzheimer’s breakthrough after drug treatment success
6 months ago

Alzheimer’s breakthrough after drug treatment success

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Lead author Dr Anthony Aggidis, a former postdoctoral research associate at Lancaster University and visiting …

How a new pill could stop Alzheimer's disease in its tracks by prompting the brain to 're-wire' itself
7 months ago

How a new pill could stop Alzheimer's disease in its tracks by prompting the brain to 're-wire' itself

Daily Mail  

A new pill could stop Alzheimer's disease in its tracks by prompting the brain to 're-wire' itself. Scientists at BnH research, the South Korean company that is developing the new pill, predict it will be a more effective way to combat the disease. This plays a key role in improving the brain's ­neuroplasticity – its ability to grow new nerve …

Diabetes drug ‘may lower risk of developing dementia’
7 months ago

Diabetes drug ‘may lower risk of developing dementia’

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Please try again later {{ /verifyErrors }} Medication used …

What are the symptoms and treatments for Alzheimer’s – as new drug is rejected
7 months, 1 week ago

What are the symptoms and treatments for Alzheimer’s – as new drug is rejected

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …

Weight-loss drug ‘could slow progression of Alzheimer’s disease’
8 months ago

Weight-loss drug ‘could slow progression of Alzheimer’s disease’

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. “While further research is needed, liraglutide may work through …

Alzheimer's drug that can slow disease gets backing from FDA advisers
9 months, 3 weeks ago

Alzheimer's drug that can slow disease gets backing from FDA advisers

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Food and Drug Administration advisers voted unanimously that the …

Alzheimer’s drug that can slow disease gets backing from FDA advisers
9 months, 3 weeks ago

Alzheimer’s drug that can slow disease gets backing from FDA advisers

Associated Press  

WASHINGTON — A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia caused by the brain-robbing disease. Food and Drug Administration advisers voted unanimously that the drug’s ability to slow the disease outweighs its risks, including side effects like brain …

FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations
9 months, 3 weeks ago

FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations

NPR  

FDA advisers strongly back new Alzheimer’s drug, despite risks and limitations toggle caption Andrew Harnik/AP Advisers to the Food and Drug Administration have recommended unanimously that the agency approve the Alzheimer’s drug donanemab. At a meeting Monday, the Peripheral and Central Nervous System Drugs Advisory Committee voted 11-0 that donanemab is effective at slowing down Alzheimer’s in the disease’s early …

Expected to be a big deal, Alzheimer's drug is pulled after disappointing sales
1 year, 2 months ago

Expected to be a big deal, Alzheimer's drug is pulled after disappointing sales

NPR  

Expected to be a big deal, Alzheimer's drug is pulled after disappointing sales Drugmaker Biogen is pulling the plug on its controversial Alzheimer's drug Aduhelm, following disappointing sales. Now Biogen says it couldn't find a partner or financing to help pay for the costly confirmatory study, so it's cutting its losses and focusing on its other FDA-approved Alzheimer's drug called …

Scientists discover there's FIVE types of Alzheimer's and are hopeful breakthrough could lead to cure
1 year, 2 months ago

Scientists discover there's FIVE types of Alzheimer's and are hopeful breakthrough could lead to cure

Daily Mail  

Scientists have discovered there are five types of Alzheimer's, and this may explain why some drugs appear to be ineffective against the condition. Dutch experts have found five subtypes of Alzheimer's disease after examining the proteins in the cerebrospinal fluid, found in the brain and spine, of over 400 patients This graphic shows the areas of the brain that shrunk …

Navigating new Alzheimer's drugs can be confusing and expensive. So do they really help patients?
1 year, 6 months ago

Navigating new Alzheimer's drugs can be confusing and expensive. So do they really help patients?

Salon  

For decades, attempts to treat or slow Alzheimer's disease — a brain disorder that causes dementia through damage to brain cells and other changes in the brain — have been dispiriting failures. "Our hope is that these are firsts for our field," Dr. Maria Carrillo, chief science officer of the Alzheimer's Association, told Salon in a video call about the …

A trial to test a new path for preventing Alzheimer’s
1 year, 7 months ago

A trial to test a new path for preventing Alzheimer’s

The Hindu  

Last month, a wave of excitement swept through the world of Alzheimer’s research after Eli Lilly published results of a trial of their drug, donanemab. Elevated levels of amyloid form plaque and trigger another protein called tau that damages brain cells, causing the cognitive decline typified by the disease. One of these is the oxidative stress hypothesis, which suggests that …

Kerala University to create awareness on Alzheimer’s disease among youngsters
1 year, 7 months ago

Kerala University to create awareness on Alzheimer’s disease among youngsters

The Hindu  

Kerala University has embarked on a drive to create awareness among school students on the increasing prevalence of dementia and Alzheimer’s disease in the State. Spearheaded by the Biochemistry department in association with the Commerce department at the university, the programme also aims at imparting knowledge in caring for a family member afflicted with Azheimer’s in view of the difficulty …

A new treatment for Alzheimer’s offers hope—but raises questions, too
1 year, 8 months ago

A new treatment for Alzheimer’s offers hope—but raises questions, too

Hindustan Times  

FOR DECADES the search for a drug to treat Alzheimer’s disease had seemed a costly wild-goose chase. In a trial involving 1,736 people showing early symptoms of Alzheimer’s, donanemab, developed by Eli Lilly, an American firm, was shown to have “significantly slowed” the progression of the disease—by 35% after 76 weeks by one measure. The result, which headlined the annual …

‘Turning point’ in the fight against Alzheimer’s as drug found to slow disease
1 year, 8 months ago

‘Turning point’ in the fight against Alzheimer’s as drug found to slow disease

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Risk can increase with age, impacting one in 14 people over the age of 65 …

New drug found to slow Alzheimer’s hailed as turning point
1 year, 8 months ago

New drug found to slow Alzheimer’s hailed as turning point

The Independent  

Get the free Morning Headlines email for news from our reporters across the world Sign up to our free Morning Headlines email Sign up to our free Morning Headlines email SIGN UP I would like to be emailed about offers, events and updates from The Independent. The charity said new treatments including donanemab – which works by removing a protein …

Why is this Alzheimer’s breakthrough so important?
1 year, 8 months ago

Why is this Alzheimer’s breakthrough so important?

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Please enter a valid email address Please enter a valid email address SIGN UP I would like to be emailed about offers, events and updates from The Independent. Scientists found that donanemab was able to slow clinical …

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’
1 year, 8 months ago

New Alzheimer’s wonder drug ‘can slow disease progression by 60pc’

The Telegraph  

The NHS has just 88 positron emission tomography scanners which can detect amyloid plaques in the brain, one of the lowest per capita in the developed world. Hilary Evans, the chief executive of Alzheimer’s Research UK said: “Probably only two per cent of the people who could benefit from these drugs would necessarily get them because of those hurdles in …

An experimental Alzheimer's drug outperforms one just approved by the FDA
1 year, 8 months ago

An experimental Alzheimer's drug outperforms one just approved by the FDA

NPR  

An experimental Alzheimer's drug outperforms one just approved by the FDA Enlarge this image toggle caption Eli Lilly and Company Eli Lilly and Company Patients in the early stages of Alzheimer's may soon have a new option to stave off the loss of memory and thinking. "This is the biggest effect that's ever been seen in an Alzheimer's trial for …

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor
1 year, 8 months ago

New drug for Alzheimer's gives hope and ushers in new era in fighting the disease, says doctor

NL Times  

Alzheimer's used to be a disease that could not be cured. On Monday, however, the results of the second new drug for Alzheimer's will be announced, and that seems to herald a new era, says neurologist Niels Prins, director of the Brain Research Center. "It will be possible to counteract the disease, and that has never been done before in …

Opinion: New Alzheimer’s drugs are costly and controversial. Are we going about this all wrong?
1 year, 9 months ago

Opinion: New Alzheimer’s drugs are costly and controversial. Are we going about this all wrong?

LA Times  

An illustration depicting neurons in a brain affected by Alzheimer’s disease, with abnormal accumulations of beta-amyloid and tau proteins shown in brown and blue, respectively. The Food and Drug Administration’s recent approval of new Alzheimer’s drugs sparked a flicker of hope for the millions affected by this devastating disease. Eli Lilly’s stock price jumped 6.7% after it announced positive results …

Breakthrough Alzheimer’s drugs could be blocked by NHS, campaigners warn
1 year, 10 months ago

Breakthrough Alzheimer’s drugs could be blocked by NHS, campaigners warn

The Telegraph  

The first drugs to slow dementia could be denied to NHS patients because of rationing, campaigners and health experts have warned. Recent weeks have seen breakthroughs in Alzheimer’s research, sparking hopes of “the beginning of the end” of the disease, but the UK’s leading dementia charity fears the drugs will be blocked by NHS rationing bodies. Alzheimer’s Research UK has …

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’
1 year, 10 months ago

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

The Independent  

The world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow cognitive and functional decline. Daniel Skovronsky, Eli Lilly’s chief scientific and medical officer, said: “This is the first phase 3 trial of any investigational medicine for Alzheimer’s disease to deliver 35% slowing of clinical …

Alzheimer’s drug lowers levels of protein known to cause disease, suggests study
1 year, 11 months ago

Alzheimer’s drug lowers levels of protein known to cause disease, suggests study

The Independent  

Sign up for our free Health Check email to receive exclusive analysis on the week in health Get our free Health Check email Get our free Health Check email SIGN UP I would like to be emailed about offers, events and updates from The Independent. The results are a significant step forward in demonstrating that we can successfully target tau …

Benefits of lecanemab, a new Alzheimer's drug, unclear for patients of color : Short Wave : NPR
2 years ago

Benefits of lecanemab, a new Alzheimer's drug, unclear for patients of color : Short Wave : NPR

NPR  

How well does a new Alzheimer's drug work for those most at risk? A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. The clinical trial for lecanemab was the most diverse for an Alzheimer's treatment to date, but it …

New insights into treatment of Alzheimer's disease: Research
2 years, 1 month ago

New insights into treatment of Alzheimer's disease: Research

Hindustan Times  

According to Alzheimer's Disease International, more than 55 million people worldwide will have Alzheimer's disease by 2020. In Alzheimer's disease, a small protein known as amyloid beta misfolds to intermediates that aggregate into larger macromolecular structures known as fibrils and plaques. Controversy over efficacy and notable side effects such as microhemorrhages and brain swelling highlight the need for better therapy …

EXPLAINER: New drug slows Alzheimer’s but comes with caveats
2 years, 2 months ago

EXPLAINER: New drug slows Alzheimer’s but comes with caveats

Associated Press  

WASHINGTON — A new Alzheimer’s drug is hitting the market — the first with clear-cut evidence that it can slow, by several months, the mind-robbing disease. In Eisai’s 18-month study of nearly 1,800 people, Leqembi appeared to delay early-stage patients from getting worse by about five months. People who got the drug still worsened but not as rapidly as those …

US approves Alzheimer’s drug that modestly slows disease
2 years, 2 months ago

US approves Alzheimer’s drug that modestly slows disease

Associated Press  

WASHINGTON — U.S. health officials on Friday approved a closely watched Alzheimer’s drug that’s been shown to modestly slow the early stages of the brain-robbing disease, albeit with potential safety risks that doctors and patients will have to carefully weigh. Last week, a congressional report found that FDA’s approval of a similar Alzheimer’s drug called Aduhelm — also from Biogen …

U.S. approves Alzheimer’s drug that modestly slows disease
2 years, 2 months ago

U.S. approves Alzheimer’s drug that modestly slows disease

LA Times  

This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. U.S. health officials on Friday approved a closely watched Alzheimer’s drug that modestly slows the brain-robbing disease, albeit with potential safety risks that patients and their doctors will have to carefully weigh. Last week, a congressional report found that FDA’s approval …

FDA approves Alzheimer's drug that appears to modestly slow disease
2 years, 2 months ago

FDA approves Alzheimer's drug that appears to modestly slow disease

NPR  

FDA approves Alzheimer's drug that appears to modestly slow disease Enlarge this image toggle caption David Duprey/AP David Duprey/AP The Food and Drug Administration has approved a drug that may help people in the early stages of Alzheimer's maintain their mental abilities. "This is a milestone for people eligible for this treatment, for their families, for the research community," says …

Probe: Alzheimer’s drug approval ‘rife with irregularities’
2 years, 3 months ago

Probe: Alzheimer’s drug approval ‘rife with irregularities’

Associated Press  

WASHINGTON — The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators and a company it’s supposed to oversee -- Aduhelm manufacturer Biogen. Thursday’s report urged the agency to “take swift action” …

Alzheimer’s drug approval by FDA ‘rife with irregularities,’ probe finds
2 years, 3 months ago

Alzheimer’s drug approval by FDA ‘rife with irregularities,’ probe finds

LA Times  

The FDA’s contentious approval of the questionable Alzheimer’s drug Aduhelm took another hit, as congressional investigators called the process “rife with irregularities.” The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical collaboration” between FDA regulators …

Explained | Will new drug slow progress of Alzheimer’s?
2 years, 3 months ago

Explained | Will new drug slow progress of Alzheimer’s?

The Hindu  

The story so far: In late November, news of the success of a drug to reduce cognitive decline in patients with Alzheimer’s disease burst on the horizon with all the promise of being a silver bullet. This class of drugs does precisely that.” As per the NEJM paper, the clinical trial, conducted over 18-months, a multi-centre, double-blind, phase 3 trial, …

Scientists hail breakthrough as drug proven to slow Alzheimer’s disease
2 years, 3 months ago

Scientists hail breakthrough as drug proven to slow Alzheimer’s disease

The Independent  

Scientists are hailing a historic step in the fight against Alzheimer’s, after a drug was proven to slow the disease in long-awaited clinical trials. Scientists also used blood tests and brain scans to search for levels of amyloid among the participants – discovering that they had fallen so significantly in those given lecanemab that some patients no longer technically met …

Is the new drug lecanemab a breakthrough for Alzheimer’s?
2 years, 4 months ago

Is the new drug lecanemab a breakthrough for Alzheimer’s?

Hindustan Times  

There’s news in the world of Alzheimer’s research. In a phase three trial, drug companies Biogen and Eisai reported this week that lecanemab, an experimental monoclonal antibody, reduced cognitive decline caused by the disease by 27% after 18 months. This trial proves that Alzheimer’s disease can be treated," Bart De Strooper, Director of the UK Dementia Research Institute, told reporters. …

Drug slows Alzheimer’s but can it make a real difference?
2 years, 4 months ago

Drug slows Alzheimer’s but can it make a real difference?

Associated Press  

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening — but the anxiously awaited new data leaves unclear how much difference that might make in people’s lives. But Dr. Ron Petersen, an Alzheimer’s expert at the Mayo Clinic, said the drug’s effect was “a modest one but I think it’s clinically meaningful” -- because even a few months’ …

Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus
2 years, 4 months ago

Alzheimer's drug from Eisai and Biogen slows cognitive decline, side-effects in focus

The Hindu  

An experimental Alzheimer's disease drug from Eisai and Biogen slowed cognitive decline in a closely watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer's, found that treatment with lecanemab reduced the …

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?
2 years, 4 months ago

Breakthrough: A drug slows Alzheimer’s by 5 months, but will it make a big difference?

Firstpost  

On Tuesday, Japanese drugmaker Eisai and its US partner Biogen reported that an experimental Alzheimer’s drug had modestly slowed the brain disease’s inevitable worsening. However, it is unclear how much of a difference this would make in people’s lives An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much …

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment
2 years, 4 months ago

New Alzheimer’s drug hailed as ‘beginning of the end’ in search for treatment

The Independent  

Get the free Morning Headlines email for news from our reporters across the world Sign up to our free Morning Headlines email Sign up to our free Morning Headlines email SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Experts have hailed the “beginning of the end” in the …

Ground-breaking Alzheimer’s drug may be ‘beginning of the end’ for disease
2 years, 4 months ago

Ground-breaking Alzheimer’s drug may be ‘beginning of the end’ for disease

The Telegraph  

A drug which slows down Alzheimer’s and reduces memory decline may be “the beginning of the end” for the disease, scientists believe. “These exciting findings represent a major step forward for dementia research and could herald a new era for people with Alzheimer’s disease,” she said. “This is the first time a drug has been shown to both reduce the …

New drug appears to slow Alzheimer’s, but can it make a real difference?
2 years, 4 months ago

New drug appears to slow Alzheimer’s, but can it make a real difference?

LA Times  

An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday — but it remains unclear how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner, Biogen, had announced earlier this fall that the drug, lecanemab, appeared to work, a badly needed bright spot after repeated disappointments in the quest for …

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking
2 years, 4 months ago

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

NPR  

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking Enlarge this image toggle caption NATIONAL INSTITUTE ON AGING, NIH/AP NATIONAL INSTITUTE ON AGING, NIH/AP An experimental drug that removes a substance called amyloid from the brain appears to slow down Alzheimer's disease. The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of …

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn
2 years, 4 months ago

Drug that reverses dementia will be wasted without better diagnosis rates, experts warn

The Telegraph  

The latest published data shows that as of 2019, Britain had just 70 PET-CT scanning locations, less than half the number of those available in comparable EU countries. “We need everyone to be told which disease is causing their dementia symptoms, and if they have Alzheimer’s disease, a follow-up scan or CSF test to check if they are amyloid positive …

Discover Related